[32,34,39] As the use of IDH1 and IDH2 inhibitors available for clinical use in R/R AML is associated with similar ORRs [80,81,82,83], the current positioning of VEN-based regimens in this population warrants further investigations. This evidence concerns the gene IDH2 and acute myeloid leukemia.